English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The objective of this article is to consider the information needs of drug purchasers; whether the Food and Drug Administration (FDA) should have a role in regulating information on the characteristics and cost-outcomes impact of new pharmaceutical products to health care purchasers; and the requirements in the new FDA Modernization Act of 1997 for "competent and reliable scientific evidence. "

Information Requirements of Health Systems as Drug Purchasers: Does the FDA Have a Role in Setting Evidentiary Standards?